Since TREM2 loss of function is one of the strongest known genetic AD risk factors, the discovery that MEK inhibition was able to raise TREM2 cell surface expression and function indicates opportunities for therapeutic intervention with these agents67. This evidence concerns the gene MAP2K7 and Alzheimer disease.